Salud financiera de hoja de balance de Avidity Biosciences
Salud financiera controles de criterios 5/6
Avidity Biosciences tiene un patrimonio de los accionistas total de $1.5B y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $1.6B y $137.4M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$1.59b |
| Patrimonio | US$1.50b |
| Total pasivo | US$137.39m |
| Activos totales | US$1.64b |
Actualizaciones recientes sobre salud financiera
Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Mar 01
Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?
Nov 04Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Apr 08Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Nov 17We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Jul 29We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely
Mar 26Recent updates
Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term
Oct 02Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders
Aug 16Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67
Aug 14Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
Aug 11Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade
Jun 14Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
May 19Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Mar 01Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Feb 29Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?
Nov 04Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Apr 08Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Nov 17Avidity slips 20% as FDA places lead asset on partial clinical hold
Sep 27We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Jul 29Avidity stock rises amid Chardan starting coverage with Buy
Jul 20Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides
Jul 12We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely
Mar 26Avidity Biosciences: Risks And Potential
Dec 09We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Nov 30Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($1.6B) de RNA superan a sus pasivos a corto plazo ($91.3M).
Pasivo a largo plazo: Los activos a corto plazo de RNA ($1.6B) superan a sus pasivos a largo plazo ($46.1M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: RNA está libre de deudas.
Reducción de la deuda: RNA no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 12.7%.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: RNA tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Datos insuficientes para determinar si RNA tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.